Nexalin Technology, Inc. announces its support for the Health Tech Investment Act (S. 1399), bipartisan legislation introduced in the United States Senate that would expand Medicare reimbursement opportunities for FDA-cleared or approved medical devices incorporating artificial intelligence (AI) or machine learning.
